Patient with metastatic lung adenocarcinoma in a supraclavicular lymph node and splenic marginal zone lymphoma. Both new diagnoses. Do you treat the lymphoma?
Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer
PURPOSE It has recently been described that alternative oncogenic drivers may be found in KRAS wild-type (KRASWT) pancreatic cancers. This study aimed to determine the incidence of targetable gene fusions ..... see more
BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors
The bromodomain and extra-terminal domain (BET) proteins are promising therapeutic targets to treat refractory solid tumors; however, inherent resistance remains a major challenge in the clinic. Recently, the emerging role ..... see more
Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia
Chronic myelomonocytic leukemia (CMML) is an aggressive hematopoietic malignancy that arises from hematopoietic stem and progenitor cells (HSPCs). Patients with CMML are frequently treated with epigenetic therapeutic approaches, in particular ..... see more
Source : https://link.springer.com/article/10.1186/s13148-020-00979-2
Exploiting KRAS-mediated metabolic reprogramming as a therapeutic target
Half of all colorectal cancers bear KRAS-activating mutations that affect the metabolic dependencies of cancer cells and drive resistance to commonly used drugs. A new study provides insights into KRAS-driven ..... see more
Comprehensive Perspective for Lung Cancer Characterisation Based on AI Solutions Using CT Images
Lung cancer is still the leading cause of cancer death in the world. For this reason, novel approaches for early and more accurate diagnosis are needed. Computer-aided decision (CAD) can ..... see more
KRAS G12V mutation upregulates PD‐L1 expression via TGF‐β/EMT signaling pathway in human non‐small‐cell lung cancer
Although clinical data suggest remarkable promise for targeting programmed cell death protein‐1 (PD‐1) and ligand (PD‐L1) signaling in non‐small‐cell lung cancer (NSCLC), it is still largely undeterm... see more
Source : https://onlinelibrary.wiley.com/doi/abs/10.1002/cbin.11524
Exquisitely Specific anti-KRAS Biodegraders Inform on the Cellular Prevalence of Nucleotide-Loaded States
Mutations to RAS proteins (H-, N-, and K-RAS) are among the most common oncogenic drivers, and tumors harboring these lesions are some of the most difficult to treat. Although covalent ..... see more
Source : https://pubs.acs.org/doi/full/10.1021/acscentsci.0c01337
Validated HPLC-MS/MS method for quantitation of AMG 510, a KRAS G12C inhibitor in a small volume of mouse plasma and its application to a pharmacokinetic study in mice.
Validated HPLC-MS/MS method for quantitation of AMG 510, a KRAS G12C inhibitor in a small volume of mouse plasma and its application to a pharmacokinetic study in mice. see more